Canaccord Genuity Group Cuts Privia Health Group (NASDAQ:PRVA) Price Target to $34.00

Key Points

• Canaccord Genuity Group trimmed its price target on Privia Health Group from $35 to $34 while keeping a buy rating, implying about 47% upside from the prior close.
• Privia Health recently reported strong Q1 results, with EPS of $0.19 versus $0.08 expected and revenue of $603.85 million versus $560.99 million estimated. Revenue rose 25.8% year over year, and the company reaffirmed full-year guidance.
• Insider selling has been notable, including share sales by a director and the CEO, with insiders selling 274,255 shares worth about $6.3 million over the last 90 days. Despite this, institutional ownership remains high at 94.48%.

Privia Health Group (NASDAQ:PRVA - Get Free Report) had its price target cut by equities researchers at Canaccord Genuity Group from $35.00 to $34.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Canaccord Genuity Group's target price points to a potential upside of 47.22% from the company's previous close.

Other equities analysts have also issued reports about the company. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Privia Health Group in a research report on Friday, March 27th. Citigroup lowered their price target on Privia Health Group from $34.00 to $32.00 and set a "buy" rating for the company in a research report on Tuesday, March 3rd. Truist Financial increased their price target on Privia Health Group from $31.00 to $33.00 and gave the company a "buy" rating in a research report on Monday, March 2nd. Piper Sandler reissued an "overweight" rating and issued a $36.00 price target on shares of Privia Health Group in a research report on Thursday, February 26th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $32.00 price target on shares of Privia Health Group in a research report on Thursday, February 26th. Eleven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $31.23.

Privia Health Group Stock Performance

Shares of Privia Health Group stock traded down $0.90 on Friday, reaching $23.10. 1,080,445 shares of the company's stock were exchanged, compared to its average volume of 870,132. The company has a market capitalization of $2.90 billion, a P/E ratio of 135.85, a price-to-earnings-growth ratio of 1.50 and a beta of 0.96. Privia Health Group has a 52 week low of $18.77 and a 52 week high of $26.51. The firm's 50-day moving average is $22.73 and its two-hundred day moving average is $23.34.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.11. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The firm had revenue of $603.85 million for the quarter, compared to analysts' expectations of $560.99 million. During the same period in the prior year, the business earned $0.22 EPS. The company's revenue for the quarter was up 25.8% compared to the same quarter last year. On average, analysts expect that Privia Health Group will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling

In other Privia Health Group news, Director Matthew Shawn Morris sold 1,017 shares of the firm's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $24.96, for a total value of $25,384.32. Following the completion of the transaction, the director owned 68,188 shares in the company, valued at $1,701,972.48. This trade represents a 1.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Parth Mehrotra sold 26,509 shares of the firm's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $22.11, for a total value of $586,113.99. Following the completion of the transaction, the chief executive officer owned 555,443 shares of the company's stock, valued at approximately $12,280,844.73. This represents a 4.56% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 274,255 shares of company stock valued at $6,299,092. 5.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Privia Health Group

Several large investors have recently added to or reduced their stakes in the business. Bayban purchased a new stake in shares of Privia Health Group in the 4th quarter valued at about $26,000. Hantz Financial Services Inc. raised its holdings in shares of Privia Health Group by 456.2% in the 4th quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company's stock valued at $27,000 after acquiring an additional 926 shares in the last quarter. Global Retirement Partners LLC raised its holdings in shares of Privia Health Group by 579.8% in the 4th quarter. Global Retirement Partners LLC now owns 1,584 shares of the company's stock valued at $38,000 after acquiring an additional 1,351 shares in the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of Privia Health Group by 48.0% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company's stock valued at $85,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Privia Health Group in the 4th quarter valued at about $93,000. Institutional investors own 94.48% of the company's stock.

Key Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Privia Health reported first-quarter results that beat revenue expectations, with sales of $603.85 million versus the $560.99 million estimate, and EPS of $0.19 versus $0.08 expected. The company also said revenue rose 25.8% year over year, and it reiterated full-year 2026 guidance. Article Title
• Positive Sentiment: The company’s updated 2026 outlook calls for revenue of $2.4 billion to $2.5 billion, which is in line with or slightly above market expectations and supports the case for continued growth. Article Title
• Neutral Sentiment: Investors are also parsing the Q1 2026 earnings call transcript and related earnings coverage for management commentary on margins, utilization trends, and the path to hitting full-year targets. Article Title
• Negative Sentiment: Two insider-selling reports may be weighing on sentiment: the CFO sold about $179,690 of stock and a director sold about $427,229 of stock, which can signal caution even when fundamentals are improving. Article Title Article Title

Privia Health Group Company Profile

Privia Health Group NASDAQ: PRVA is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.